Treatment of chronic hepatitis B with the combination of pegylated interferon with lamivudine

Hepatology Research

Volumn 37, Issue SUPPL. 1, 2007, Pages

  Marcellin, Patrick ^a   Lada, Olivier ^a   Asselah, Tarik ^a  

^a CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

Author keywords

Antiviral; Combination therapy; Interferon; Lamivudine; Nucleoside analog; Pegylation

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ALPHA2A INTERFERON; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RNA DIRECTED DNA POLYMERASE; TELBIVUDINE; TENOFOVIR; VIRUS DNA; VIRUS ENZYME;

ABNORMAL LABORATORY RESULT; ANTIVIRAL ACTIVITY; CELLULAR IMMUNITY; CHRONIC HEPATITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME INHIBITION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL; LONG TERM CARE; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRUS INHIBITION; VIRUS RESISTANCE; VIRUS STRAIN;

EID: 34447620676     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00106.x     Document Type: Conference Paper

References (26)

1. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: Summary of a workshop. Gastroenterology 2001; 120: 1828-53.
2. EASL. Consensus statement (long version). EASL International Consensus Conference on Hepatitis B. J Hepatol 2003; 39 (Suppl. 1): S3-25.
3. Conjeevaram HS, Lok AS. Management of chronic hepatitis B. J Hepatol 2003; 38 (Suppl. 1): S90-103.
4. Marcellin P, Asselah T, Boyer N. Treatment of chronic hepatitis B. J Viral Hepat 2005; 12: 333-45.
5. Thomas H, Foster G, Platis D. Mechanisms of action of interferon and nucleoside analogues. J Hepatol 2003; 39: S93-8.
6. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. An Inter Med 1993; 119: 312-23.
7. Thomas HC, Karayiannis P, Brook G. Treatment of hepatitis B virus infection with interferon. Factors predicting response to interferon. J Hepatol 1991; 13: S4-7.
8. Brunetto MR, Aragon Rodriguez U, Bonino F. Hepatitis B virus mutant. Intervirology 1999; 42: 69-80.
9. Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002; 36: 219-26.
10. Lai CL, Chien RW, Leung NWY et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med, 1998; 339: 61-8.
11. Dienstag JL, Schiff E, Wright T et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-63.
12. Schalm SW, Heathcote J, Cianciara J et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial. Gut 2000; 46: 562-8.
13. Schiff ER, Dienstag JL, Karayalcin S et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 2003; 38: 818-26.
14. Perrillo RP, Lai CL, Liaw YF et al. predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36: 186-94.
15. Leung NW, Lai CL, Chang TT et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3years of therapy. Hepatology 2001; 33: 1527-32.
16. Liaw YF, Leung NW, Chang TT et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119: 172-80.
17. Tassopoulos N, Volpes R, Pastore G et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999; 29: 889-96.
18. Lau DT, Khokhar MF, Doo E et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000; 32: 828-34.
19. Lindsay KL, Trépo C, Heintges T et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403.
20. Zeuzem S, Feinman SV, Rasenack J et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-72.
21. Cooksley G, Piratvisuth T, Lee SD et al. Peginterferon alpha 2a (40kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003; 10: 298-305.
22. Lau GK, Piratvisuth T, Luo KX et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95.
23. Marcellin P, Lau GK, Bonino F et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17.
24. Schalm SW. Combination therapy for chronic hepatitis B. J Hepatol 2003; 39: S146-50.
25. Janssen HL, van Zonneveld M, Senturk H et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial. Lancet 2005; 365: 123-9.
26. Marcellin P, Bonino F, Lau GK et al. Virological and biochemical response in patients with HBeAg-negative CHB treated with Peginterferon alpha 2a ± lamivudine: 3 years follow-up results. J Hepatol 2007; 46 (Suppl. 1): S25. [Abstract #53].